Stevens Capital Management LP Sells 31,953 Shares of Kenvue Inc. $KVUE

Stevens Capital Management LP decreased its holdings in Kenvue Inc. (NYSE:KVUE) by 75.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 10,485 shares of the company’s stock after selling 31,953 shares during the period. Stevens Capital Management LP’s holdings in Kenvue were worth $170,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its position in Kenvue by 1.8% in the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after acquiring an additional 4,101,880 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Kenvue by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock valued at $1,021,267,000 after purchasing an additional 604,953 shares in the last quarter. Independent Franchise Partners LLP grew its holdings in shares of Kenvue by 233.4% during the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after purchasing an additional 21,886,537 shares during the last quarter. American Century Companies Inc. increased its position in Kenvue by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock worth $633,447,000 after purchasing an additional 8,436,166 shares in the last quarter. Finally, Norges Bank acquired a new position in Kenvue during the 2nd quarter worth approximately $537,418,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insiders Place Their Bets

In other news, Director Jeffrey C. Smith bought 3,200,000 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were acquired at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the acquisition, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.17% of the stock is owned by corporate insiders.

Kenvue Price Performance

Kenvue stock opened at $18.73 on Monday. The stock’s 50 day moving average is $17.54 and its 200 day moving average is $17.59. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The firm has a market cap of $35.88 billion, a P/E ratio of 24.32, a P/E/G ratio of 4.29 and a beta of 0.59. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a net margin of 9.72% and a return on equity of 19.86%. The business had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same quarter in the prior year, the firm posted $0.26 EPS. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be given a dividend of $0.2075 per share. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio is 107.79%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on KVUE shares. Zacks Research raised shares of Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Canaccord Genuity Group upped their target price on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the company from $23.00 to $18.00 in a research report on Friday, January 30th. Finally, Citigroup boosted their price target on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday. Four analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.08.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.